Fanconi Anemia, Complementation Group D1 clinical trials
The registry lists 33 studies for Fanconi Anemia, Complementation Group D1 across more than 10 countries. 4 are recruiting or about to start. 8 of them are mainly about Fanconi Anemia, Complementation Group D1 (how this is decided). Per ClinicalTrials.gov, last updated 2026-09-17.
Get an email when these change. Save the Fanconi Anemia, Complementation Group D1 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
AstraZeneca (7) · National Cancer Institute (NCI) (2) · University Hospital, Montpellier (1) · N.N. Petrov National Medical Research Center of Oncology (1) · Assistance Publique - Hôpitaux de Paris (1) · University of Utah (1) · Organisation for Oncology and Translational Research (1) · Beth Israel Deaconess Medical Center (1)
What is being tested here
Drugs under test in Fanconi Anemia, Complementation Group D1 studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Olaparib | 2 | 0 | 9 |
| Carboplatin | 1 | 0 | 2 |
| Vilastobart | 1 | 0 | 1 |
| Pembrolizumab | 1 | 0 | 1 |
| Talazoparib | 0 | 0 | 1 |
| Iniparib | 0 | 0 | 1 |
| Trabectedin | 0 | 0 | 1 |
Drug classes tested here PARP inhibitors 3 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The study
- Aug 2027Carboplatin or Olaparib for BRcA Deficient Prostate Cancer · VA Office of Research and Development
Who these studies take
Of the 3 Fanconi Anemia, Complementation Group D1 studies recruiting now, 3 (100%) set no upper age limit and 0 (0%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 1 (33%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 2 (67%) | 3 (100%) |
| 30 | 2 (67%) | 3 (100%) |
| 40 | 2 (67%) | 3 (100%) |
| 50 | 2 (67%) | 3 (100%) |
| 65 | 2 (67%) | 3 (100%) |
| 75 | 2 (67%) | 3 (100%) |
| 85 | 2 (67%) | 3 (100%) |
Across all 33 studies, recruiting or not: 9% stop at 75 or younger and 0% at 65; 6% take children; 55% are for women only and 6% for men only; 18% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 33 of 33. search them.
- Carboplatin or Olaparib for BRcA Deficient Prostate CancerRecruitingNCT04038502Phase 21 country
- Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced MalignanciesRecruitingNCT06458712Phase 15 countries
- Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PCNot yet recruitingNCT07765836Phase 21 country
- Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast CancerRecruitingNCT05485766Phase 21 country
- Combination of Mitomycin and Carboplatin in Neoadjuvant Therapy in BRCA-associated Triple-negative Locally Advanced Breast CancerActive, not recruitingNCT07821229Not applicable1 country
- FaCT Trial (Facilitated Cascade Testing Trial)Active, not recruitingNCT04613440Not applicable1 country
- Olaparib In Metastatic Breast CancerActive, not recruitingNCT03344965Phase 21 country
- Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian CancerCompletedNCT00753545Phase 217 countries
- A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)CompletedNCT00516373Phase 14 countries
- Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast CancerCompletedNCT00494234Phase 28 countries
- C-PATROL - Non-interventional Study (NIS) to Collect Clinical and Patient Reported Outcome Data in an Olaparib Treated BRCAm+ PSR Ovarian Cancer PopulationCompletedNCT025034361 country
- Lavage of the Uterine Cavity for the Diagnosis of Serous Tubal Intraepithelial CarcinomaCompletedNCT02039388Not applicable8 countries
- Prevalence of HRR-related Genes Mutations and Prognosis in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients in Real World SettingCompletedNCT044252001 country
- A Qualitative Exploration of the Impact of Positive BRCA1/2 Mutation Status on the Lives of Young WomenCompletedNCT008580781 country
- Cancer of the Pancreas Screening Study (CAPS 3)CompletedNCT004389061 country
- Methods in Education for Breast Cancer GeneticsCompletedNCT00001806Phase 31 country
- Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian CancerCompletedNCT00628251Phase 29 countries
- Comparison to Psychological, Medical and Emotional Influencing Communication and Achievement Factors to Oncogenetics TestsCompletedNCT03889171
- Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced CancerCompletedNCT02418624Phase 11 country
- Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid TumorsCompletedNCT01286987Phase 12 countries
- Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian CancerCompletedNCT00494442Phase 25 countries
- Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT01339650Phase 11 country
- Evaluation of Tomosynthesis for Characterization and the Management of Breast LesionsStatus unknownNCT02959398Not applicable1 country
- Genetic Counseling in African American WomenCompletedNCT00419510Not applicable1 country
- Risk Education and Assessment for Cancer HeredityCompletedNCT01346761Not applicable1 country
- Clinical Outcomes in Hereditary CancerWithdrawnNCT005800211 country
- Lynne Cohen Consortium Project: Multi-Center Database/RegistryCompletedNCT007769581 country
- National Screening in Denmark With MR Versus Mammography and Ultrasound of Women With BRCA1 or BRCA2 MutationsStatus unknownNCT00413491Phase 41 country
- Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00677079Phase 21 country
- Study With Trabectedin in BRCA1 and BRCA2 Mutation Carrier and BRCAness Phenotype Ovarian CancerStatus unknownNCT01772979Phase 21 country
- Counseling Interventions for BRCA 1/2 Cancer Susceptibility TestingCompletedNCT00165152Not applicable1 country
- High Risk Breast Cancer Screening ProgramStatus unknownNCT005095091 country
- Establishing the Incidences of BRCA1 and BRCA2 Mutation by Combining DHPLC and Direct Sequencing in Ovarian CancerStatus unknownNCT001558961 country